Plasma proteomics linking primary and secondary diseases: Insights into molecular mediation from UK Biobank data.
Measuring specific proteins in blood can better predict which people will develop secondary diseases, improving early detection beyond traditional risk factors.
Plasma proteomics analysis of 53,030 UK Biobank participants identifies 998 protein-mediation pathways linking cardiometabolic conditions (diabetes, hypertension, dyslipidemia) to 18 downstream disease outcomes. GDF15 and ACE2 emerge as MR-validated causal mediators, and incorporating 337 mediator proteins into ML models improves secondary disease risk prediction beyond conventional clinical factors.
What the study was
- Study design
- cohort_study
- Population
- UK Biobank participants with longitudinal follow-up
- Sample size
- 53030
- Category
- Population Health / Proteomics
- Maturity
- Validated
- Journal
- Med
Why it surfaced
Comprehensive plasma proteomics mediation map (53,030 participants); 998 pathways; GDF15/ACE2 MR-validated as causal mediators; ML risk models improved; NIH/AHA funded; Med (Cell Press) journal; University of Michigan.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.